Literature DB >> 861496

Cefoxitin: a hospital study.

A M Geddes, L P Schnurr, A P Ball, D McGhie, G R Brookes, R Wise, J Andrews.   

Abstract

Cefoxitin is a new cephamycin antibiotic that has recently become available for clinical trial. We report here the results of an uncontrolled trial of cefoxitin treatment in 31 hospital patients with various acute infections, 20 of whom were cured. Serum, urine, and bile concentrations of cefoxitin greatly exceeded the minimum inhibitory concentration (MIC) required for clinically important Gram-negative organisms. We conclude that cefoxitin will have a place in the management of serious infections, particularly in the abdominal cavity and renal tracts.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 861496      PMCID: PMC1606712          DOI: 10.1136/bmj.1.6069.1126

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

1.  Semisynthetic cephalosporins via a novel acyl exchange reaction.

Authors:  S Karady; S H Pines; L M Weinstock; F E Roberts; G S Brenner; A M Hoinowski; T Y Cheng; M Sletzinger
Journal:  J Am Chem Soc       Date:  1972-02-23       Impact factor: 15.419

2.  Cephamycins: a review, prospects and some original observations.

Authors:  J M Hamilton-Miller; W Brumfitt
Journal:  Infection       Date:  1975       Impact factor: 3.553

3.  Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin.

Authors:  R C Moellering; M Dray; L J Kunz
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

4.  Comparative study of the in vitro antibacterial activity of cefoxitin, cefuroxine, and cephaloridine.

Authors:  R Norrby; J E Brorsson; S Seeberg
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

5.  Cefuroxime, a new cephalosporin antibiotic: activity in vitro.

Authors:  C H O'Callaghan; R B Sykes; A Griffiths; J E Thornton
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

6.  Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

7.  Cefoxitin, a semisynthetic cephamycin antibiotic: in vivo evaluation.

Authors:  A K Miller; E Celozzi; Y Kong; B A Pelak; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

8.  Cefoxitin, a new semi-synthetic cephamycin: an in-vitro and in-vivo comparison with cephalothin.

Authors:  J Kosmidis; J M Hamilton-Miller; J N Gilchrist; D W Kerry; W Brumfitt
Journal:  Br Med J       Date:  1973-12-15
  8 in total
  6 in total

1.  Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazole.

Authors:  J A Bosso; R A Prince
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

Authors:  J S Solomkin; J L Meakins; M D Allo; E P Dellinger; R L Simmons
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

3.  Pharmacokinetics of cefoxitin in patients with normal or impaired renal function.

Authors:  M J Garcia; A Dominguez-Gil; J M Tabernero; J A Sanchez Tomero
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 4.  Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-01       Impact factor: 9.546

5.  Clinical trial of cefonicid for treatment of skin infections.

Authors:  D H Gremillion; R E Winn; E Vandenbout
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

6.  Microbiological Air Quality and Drug Resistance in Airborne Bacteria Isolated from a Waste Sorting Plant Located in Poland-A Case Study.

Authors:  Ewa Brągoszewska; Izabela Biedroń; Wojciech Hryb
Journal:  Microorganisms       Date:  2020-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.